Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has granted stock options to five new employees. The options allow the purchase of 130,600 shares of common stock at an exercise price of $11.35 per share, equal to the last reported sale price on September 3, 2024. These inducement grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with a 10-year term. The options were granted under Olema's 2022 Inducement Plan as part of the company's employee retention and attraction strategy.
Olema Pharmaceuticals (Nasdaq: OLMA), una compagnia biofarmaceutica in fase clinica focalizzata su terapie mirate per i tumori femminili, ha concesso opzioni su azioni a cinque nuovi dipendenti. Le opzioni consentono l'acquisto di 130.600 azioni ordinarie a un prezzo di esercizio di $11,35 per azione, corrispondente all'ultimo prezzo di vendita riportato il 3 settembre 2024. Queste concessioni di incentivo, approvate ai sensi della Regola di Quotazione Nasdaq 5635(c)(4), maturano in quattro anni con un periodo di validità di 10 anni. Le opzioni sono state concesse nell'ambito del Piano di Incentivi 2022 di Olema come parte della strategia dell'azienda per la retention e l'attrazione dei dipendenti.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica centrada en terapias dirigidas para cánceres femeninos, ha otorgado opciones de acciones a cinco nuevos empleados. Las opciones permiten la compra de 130,600 acciones ordinarias a un precio de ejercicio de $11.35 por acción, igual al último precio de venta informado el 3 de septiembre de 2024. Estas concesiones de incentivo, aprobadas bajo la Regla de Cotización 5635(c)(4) de Nasdaq, se consolidan en cuatro años con un plazo de 10 años. Las opciones se otorgaron bajo el Plan de Incentivos 2022 de Olema como parte de la estrategia de la empresa para la retención y atracción de empleados.
올레마 제약(Olema Pharmaceuticals, Nasdaq: OLMA)은 여성 암을 위한 표적 치료에 주력하는 임상 단계의 생명공학 회사로, 다섯 명의 새로운 직원에게 주식 선택권을 부여했습니다. 이 선택권은 130,600 주의 보통주를 주당 $11.35의 행사 가격으로 구매할 수 있도록 하며, 이는 2024년 9월 3일에 보고된 마지막 판매 가격과 동일합니다. 이 유도 보상은 Nasdaq 상장 규칙 5635(c)(4) 아래에서 승인되었으며, 4년에 걸쳐 배분되고, 10년의 유효 기간을 가집니다. 이 선택권은 올레마의 2022 유도 플랜에 따라 직원 retention 및 유치를 위한 전략의 일환으로 부여되었습니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique axée sur des thérapies ciblées pour les cancers féminins, a accordé des options d'achat d'actions à cinq nouveaux employés. Ces options permettent l'achat de 130 600 actions ordinaires à un prix d'exercice de 11,35 $ par action, égal au dernier prix de vente signalé le 3 septembre 2024. Ces concessions d'incitation, approuvées selon la règle d'inscription Nasdaq 5635(c)(4), s'acquièrent sur quatre ans avec un terme de 10 ans. Les options ont été accordées dans le cadre du Plan d'incitation 2022 d'Olema, comme partie de la stratégie de l'entreprise pour la rétention et l'attraction des employés.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien für Frauenkrebserkrankungen konzentriert, hat Aktienoptionen an fünf neue Mitarbeiter vergeben. Die Optionen ermöglichen den Kauf von 130.600 Aktien zu einem Ausübungspreis von 11,35 $ pro Aktie, was dem zuletzt am 3. September 2024 gemeldeten Verkaufs preis entspricht. Diese Induktionsvergabe, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurde, wird über vier Jahre mit einer Laufzeit von 10 Jahren fällig. Die Optionen wurden im Rahmen des Olema 2022 Induktionsplans als Teil der Strategie des Unternehmens zur Mitarbeiterbindung und -gewinnung vergeben.
- Olema is actively expanding its workforce, potentially indicating growth or increased operational capacity
- The company has implemented an employee incentive program through stock options, which may help attract and retain talent
- The issuance of new stock options may lead to potential dilution for existing shareholders
SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to five new employees to purchase an aggregate of 130,600 shares of the Company's common stock, effective as of September 3, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of September 3, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Investor Relations and Communications
ir@olema.com
FAQ
How many new employees received stock options from Olema Oncology (OLMA) on September 3, 2024?
What is the exercise price of the stock options granted by Olema Pharmaceuticals (OLMA) on September 3, 2024?
How many shares of Olema Oncology (OLMA) common stock can be purchased with the newly granted stock options?
What is the vesting schedule for the stock options granted by Olema Pharmaceuticals (OLMA) on September 3, 2024?
